MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage III melanoma. It is the third such reveal in weeks, following the drug’s success as a monotherapy in NSCLC with any PD-L1 expression but failure as a combo therapy in unresectable or metastatic melanoma.
Ook interessant voor je
Reageer